Price Alert

Blueprint Medicines Corpo... (BPMC)

NASDAQ: BPMC · Real-Time Price · USD

129.46

0.18 (0.14%)

At close: Jul 17, 2025, 3:59 PM

Blueprint Medicines Statistics

Share Statistics

Blueprint Medicines has 64.58M shares outstanding. The number of shares has increased by 2.08% in one year.

Shares Outstanding	64.58M
Shares Change (YoY)	2.08%
Shares Change (QoQ)	1.19%
Owned by Institutions (%)	99.99%
Shares Floating	60M
Failed to Deliver (FTD) Shares	38
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 1.67M, so 0% of the outstanding shares have been sold short.

Short Interest	1.67M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -81.72 and the forward PE ratio is 140.72. Blueprint Medicines's PEG ratio is 0.94.

PE Ratio	-81.72
Forward PE	140.72
PS Ratio	10.77
Forward PS	8.8
PB Ratio	18.36
P/FCF Ratio	-27.8
PEG Ratio	0.94

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Blueprint Medicines.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.85, with a Debt / Equity ratio of 1.57.

Current Ratio	2.85
Quick Ratio	2.8
Debt / Equity	1.57
Debt / EBITDA	24.39
Debt / FCF	-2.38
Interest Coverage	-3.08

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$746.08K
Profits Per Employee	$-98.37K
Employee Count	682
Asset Turnover	0.43
Inventory Turnover	1.48

Taxes

Income Tax	1.23M
Effective Tax Rate	-1.86%

Stock Price Statistics

The stock price has increased by 38.15% in the last 52 weeks. The beta is 0.83, so Blueprint Medicines's price volatility has been higher than the market average.

Beta	0.83
52-Week Price Change	38.15%
50-Day Moving Average	118.77
200-Day Moving Average	99.62
Relative Strength Index (RSI)	76.66
Average Volume (20 Days)	3,287,638

Income Statement

In the last 12 months, Blueprint Medicines had revenue of 508.82M and earned -67.09M in profits. Earnings per share was -1.07.

Revenue	508.82M
Gross Profit	488.66M
Operating Income	-212.04M
Net Income	-67.09M
EBITDA	19.23M
EBIT	2.94M
Earnings Per Share (EPS)	-1.07

Full Income Statement

Balance Sheet

The company has 102.01M in cash and 469.11M in debt, giving a net cash position of -367.09M.

Cash & Cash Equivalents	102.01M
Total Debt	469.11M
Net Cash	-367.09M
Retained Earnings	-2.41B
Total Assets	1.2B
Working Capital	451.49M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -192.59M and capital expenditures -4.63M, giving a free cash flow of -197.22M.

Operating Cash Flow	-192.59M
Capital Expenditures	-4.63M
Free Cash Flow	-197.22M
FCF Per Share	-3.14

Full Cash Flow Statement

Margins

Gross margin is 96.04%, with operating and profit margins of -41.67% and -13.19%.

Gross Margin	96.04%
Operating Margin	-41.67%
Pretax Margin	-12.94%
Profit Margin	-13.19%
EBITDA Margin	3.78%
EBIT Margin	-41.67%
FCF Margin	-38.76%

Dividends & Yields

BPMC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for BPMC is $129, which is -0.4% lower than the current price. The consensus rating is "Hold".

Price Target	$129
Price Target Difference	-0.4%
Analyst Consensus	Hold
Analyst Count	16

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	3.68
Piotroski F-Score	4